{"name":"VivaVision Biotech, Inc","slug":"vivavision-biotech-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"VVN001 Ophthalmic Solution, Vehicle","genericName":"VVN001 Ophthalmic Solution, Vehicle","slug":"vvn001-ophthalmic-solution-vehicle","indication":"Administration of other eye medications","status":"phase_3"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"VVN001 Ophthalmic Solution, 5%","genericName":"VVN001 Ophthalmic Solution, 5%","slug":"vvn001-ophthalmic-solution-5","indication":"Treatment of non-infectious uveitis affecting the posterior segment of the eye","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"VVN461 Ophthalmic Solution 1.0%","genericName":"VVN461 Ophthalmic Solution 1.0%","slug":"vvn461-ophthalmic-solution-1-0","indication":"Ocular surface disease (specific indication not publicly detailed)","status":"phase_3"}]}],"pipeline":[{"name":"VVN001 Ophthalmic Solution, Vehicle","genericName":"VVN001 Ophthalmic Solution, Vehicle","slug":"vvn001-ophthalmic-solution-vehicle","phase":"phase_3","mechanism":"VVN001 Ophthalmic Solution, Vehicle is a topical ophthalmic solution used to facilitate the administration of other eye medications.","indications":["Administration of other eye medications"],"catalyst":""},{"name":"VVN001 Ophthalmic Solution, 5%","genericName":"VVN001 Ophthalmic Solution, 5%","slug":"vvn001-ophthalmic-solution-5","phase":"phase_3","mechanism":"VVN001 Ophthalmic Solution, 5% is a corticosteroid that reduces inflammation in the eye.","indications":["Treatment of non-infectious uveitis affecting the posterior segment of the eye"],"catalyst":""},{"name":"VVN461 Ophthalmic Solution 1.0%","genericName":"VVN461 Ophthalmic Solution 1.0%","slug":"vvn461-ophthalmic-solution-1-0","phase":"phase_3","mechanism":"VVN461 is an ophthalmic solution designed to treat ocular surface disease by modulating inflammatory pathways in the eye.","indications":["Ocular surface disease (specific indication not publicly detailed)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQbk91SWw5cmEtMzhiRXhJNmRsVnpBaWhfcXg0T0h5Szh4Tm1zSGk0V1h1emxUcVRmaVgyczdpM1ZXXzJFYVBvWXRuNGpXckd1NjJzWmU0ZVFNMmpJSFl6dTFDR0I3Zzk0VURWZmo0bGl1Zl9hbHhOY1k3elhSNXlXM09HeDlMNk5mSFlZajQxSDctOGl5c0ZtYm9fbnZ6aEU?oc=5","date":"2026-04-03","type":"earnings","source":"openPR.com","summary":"Open Angle Glaucoma Market: Expanding Revenue Landscape to 2034 - openPR.com","headline":"Open Angle Glaucoma Market: Expanding Revenue Landscape to 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOX1FPODRsS01iMVItemVWNlotTWtIWTItWGNNRV9zQlgtbEwyOWxMSE54LXZKQWtvQ2dpR0tOS3ctcm05RUlUd19hNFVxaXdhc1REVmMyd0EyNEhoRkcyZ00tQVJ6alprRUhzZHJmOXJNOFlqa2hSaHBUY0JLa2gxcmhzaENKSW5kbVZCeFhEeWRMelFCemc?oc=5","date":"2026-02-17","type":"trial","source":"Endpoints News","summary":"Six biotechs file for HKEX listing; Faraday Pharmaceuticals shutters - Endpoints News","headline":"Six biotechs file for HKEX listing; Faraday Pharmaceuticals shutters","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwJBVV95cUxONzJwRzBpN1dGQ1h1QkRLdEFDQnRrcTJhMUkwSTJRdk9uZWJkVUZOd2VNel8tTWlJYzZkSzdJSG9nRXRuZFpkVFpEV1RKMDBvTWlkNnRaN3BzVUU5SWdZZDVwc1djWWhEaVhPRjlxWS15RDRJbm9hS29hQllqQktObGtUTDZ6OHlRQ2F4ZGlNQzFRUlpNakd2MkdiU244N3hLX3lka3FHS3VoTlVtbzJ2LXk2UHJ0ckZ5VjdGUi1MSUFRaU5YX2kxb2tOUnJoUFItM256NTFaaHhRSlpFRjdNVWE1eEZmY3RzdW5LZmZGcmI4dEVaNFlWcmZFQ3RXRVhfaGctMVhYTm9pdVMyaUx4ZC1feDh1SGk2czRLRUJzaDQydWVlWUdQUFR6bzJ5c09PaUtCWFNoQQ?oc=5","date":"2025-02-26","type":"pipeline","source":"GlobeNewswire","summary":"DURYSTA’s Market Potential Across the 7MM is Set to Soar - GlobeNewswire","headline":"DURYSTA’s Market Potential Across the 7MM is Set to Soar","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNUTlueFcxMloxdHhmMklNRmVicU9oc1hZMkY1dElEeUNUeWJTdmV2YzJycktUNG1STmthZ1FOLXBweTM4WTZCZVF4TXc3VHVXS01rdUhfMXVUZmp4N3VBQUR5RkI2M2Q3b1pGaGNzeG5OZDF1YmdHWFZVQkkyMS1HTV9zMG96WEluMk12MU5XaEVWWHhhZXpmZ19Fd2pSelNuN0FoVXozMERsVHd0YnJVdlYyb1d1LTNJU1NQdWItM3hxZ3RlZ01mcw?oc=5","date":"2025-01-28","type":"pipeline","source":"prnewswire.com","summary":"Dry Eye Disease Market to Observe Stupendous Growth by 2034 | DelveInsight - prnewswire.com","headline":"Dry Eye Disease Market to Observe Stupendous Growth by 2034 | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxQeHhISHVyb2Z5d2h0aGoyZW4takJhLTlQaDlYbFFlaTRvMnBrN3h6cEttemhWelM0SzRkRFlzVlkzTkdET1dqb2xZcVdjZ0pKWGZIVnd0QnBDRHJjN0J3WXZmaWRpU0g4VndCYk9zSE94dF80VWNWX01MYXpJci02SFozdHlOdlR2TkM0ckNpdjBzVHE5U2hVUzc0U0dMODBXZkNYY08xOFh1OE53eWRRYi03cUIwQlh3d0JvTU41djhNMm9Mc3hBelZldmRETjlQd3ptNmlkY2RuQm9zR1F4WlMzeVQyUnhxeDdBSUNSbjRJX1NLVjI0ZEs0bmY3dWh4dDd1TFZKbjlpNTlIeXdqdm9PWG1mS3hEMTNTTmRjZw?oc=5","date":"2025-01-20","type":"trial","source":"GlobeNewswire","summary":"Advancements in Ocular Hypertension Clinical Trial Pipeline - GlobeNewswire","headline":"Advancements in Ocular Hypertension Clinical Trial Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgJBVV95cUxNZVJpZ0ZwaXBDUGZoZFgxVXBzSFVGc25JekJ2bmZzT3dFYVZQU1QyNXk5N3Fha05LRXpnQXNkX2Fld1FHNURoQWdvZ0FMWGd2NHkzSTNnVmpsMVhKNV9ZenJwYWJSR21BWGI0MHRUeFJ2VW5vWEFsSVFSaXBINUV1VEctbW5XaXVXVWpZU2dwTnVfOFg2RjNmTjJ6ZE5IQnJ5YVlnMWxnTWdvRzd4UE9NQV82QUFLN1FjcG94NHdKNXotUlJMbVNxemhUUVhQakNzeG5qSUtkZEQ2dXMyMjBuNWZuWDN0Y3J6bk5MdTY5Q3VLaXZoU3JqRkNBT041YmMxd0FsQm9R?oc=5","date":"2024-12-05","type":"trial","source":"Ophthalmology Times","summary":"VivaVision Biotech reports positive Phase 2 trial results of VVN461 for postoperative inflammation treatment following cataract surgery - Ophthalmology Times","headline":"VivaVision Biotech reports positive Phase 2 trial results of VVN461 for postoperative inflammation treatment following c","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxQX0V5SWRMRXRic3pOekZOSXJjS2ZLckQ5cGMyaUhLWkdPcEU0UXVPc0RGanlFcEd6YTZuOW8wb0M1Y2JocnZVWjdfaC1SY0tlYkNlS1VQaHZmVG1XRE92Qjlmcjl0SXAyUENNSVRTMHNta2xaSFQzZHh0eG5NSDVsOXVGSDJwRGI2ZDJweXJkVnRKOGhLZXc5VnY2bjRGRXpJV043MHNCckllSFMwWUJHbHNmcGtTWHR5NVVvZVJEdFV0SG81QTdNWEwzRU5XRGZDT1RrOXpyVXVmRllDS2hYZm8yc0Y2Vi1zSkVnNnVuOVM0OC1odnhXS3pDR0lNX1p5SzQydGctR09nN2pDVFBxMVBOMDZxZ0s1YlVscFQ2ZklfUjhjT0NIdmNlNFZFZw?oc=5","date":"2024-12-04","type":"trial","source":"GlobeNewswire","summary":"VivaVision Announces Positive Topline Results from Phase 2 - GlobeNewswire","headline":"VivaVision Announces Positive Topline Results from Phase 2","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxOcTFsdWh2ejBfaDNLQ1RrdmxPUTFpVkxaUXhLRHB0SDJBc2R5ZkUyaTNhMWp3OGJJZVB5b3pheUhVNTFqVVl5TVVlZml5Rk5qSHBMelVxV1BORjVySEJrYkxPRVk4SU1QaC1sNno2M2JoU0R5UXFyTDFCcWtTa0F5RF90aXZqeDNOT2dudWVGbkoweEdaZnpsYmRNeGl1aVJSR1ZHczJ4TlphWkRlcU1DbEU0V1RjWHBDQmVoaF9zRzdSZXc4S0RWQXozRkVmNEY0U2Q0eUIybWs4TmZrMnAxbFdocDAyNkZYRjQxejN0SEVqVGlZUXVVbFlLUHZoSG9OTUE?oc=5","date":"2023-05-18","type":"trial","source":"prnewswire.com","summary":"Glaucoma Clinical Trial Pipeline Accelerates as 45+ Pharma Companies Rigorously Developing Drugs for the Market Entry - prnewswire.com","headline":"Glaucoma Clinical Trial Pipeline Accelerates as 45+ Pharma Companies Rigorously Developing Drugs for the Market Entry","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAJBVV95cUxPR3FjTEF0T3FfRE9RVm8xUUxHM1Y0aE9GUmxoZVMydkg2TWV5UU9fbGNmeVBWUlY1OFcyeUhkY1UtMDNCaDRzSDNMUHlqUHJQRDJaMGZGWWo0OWhidFdqNWVVLTBRXzY3N0FNV1Z3RkotUXppSFNmaWR0a3RqNG5peFFqdk42Sy0wcEt6OVVBbUd1NXhXSDNuLTBQZEF0d0tWZmlBTGNNVFVXQjhwckp6TFR2X0tkX29SNVUtRlpUMkZCOTY4ZHI5QVVDRU1LbzZRY0wyM05xREJwUmx3SzlxRW9VX0NhYVk1YjliQTN4akwxNG0tdFd2V2JpQXROTWZCNDctcXZha011eTlaWnlQMkNRSzg?oc=5","date":"2022-03-22","type":"trial","source":"prnewswire.com","summary":"VivaVision Biotech Announces Positive Topline Results of VVN001 in the Phase 2 Clinical Study for the Treatment of Dry Eye Disease - prnewswire.com","headline":"VivaVision Biotech Announces Positive Topline Results of VVN001 in the Phase 2 Clinical Study for the Treatment of Dry E","sentiment":"positive"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_3":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}